Opthea
Clinical-stage biopharmaceutical company developing novel therapies for retinal diseases, with lead candidate sozinibercept targeting wet age-related macular degeneration and diabetic macular edema.
Website
https://www.opthea.comLocation
Melbourne, Australia
Founded
2007
Investors
1
Categories
biotech, ophthalmology, retinal-diseases, wet-amd
Notes
Opthea is a clinical-stage biopharmaceutical company focused on developing transformative therapies for retinal diseases. The company's lead candidate, sozinibercept (OPT-302), is a VEGF-C/D inhibitor designed to be used in combination with existing anti-VEGF treatments to improve outcomes for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea's approach targets additional growth factors beyond VEGF-A, which is targeted by current standard of care treatments.
Team
- Frederic Guerard, Ph.D. - Chief Executive Officer
- Megan Baldwin, Ph.D. - Co-Founder & Chief Scientific Officer
Additional Research Findings
- Founded in 2007 in Melbourne, Australia
- Listed on NASDAQ (ticker: OPT) and ASX
- Portfolio company of Abingworth
- Lead candidate sozinibercept (OPT-302) - VEGF-C/D inhibitor
- Phase 3 trials for wet AMD (ShORe and COAST studies)
- Combination therapy approach with existing anti-VEGF treatments
- Focus on improving vision outcomes beyond current standard of care
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |